Review
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Apr 27, 2023; 15(4): 477-496
Published online Apr 27, 2023. doi: 10.4254/wjh.v15.i4.477
Comparison between metabolic-associated fatty liver disease and nonalcoholic fatty liver disease: From nomenclature to clinical outcomes
Mohammad Alomari, Mamoon Ur Rashid, Pravallika Chadalavada, Jonathan Ragheb, Hammad Zafar, Zoilo Karim Suarez, Shrouq Khazaaleh, Adalberto Jose Gonzalez, Fernando J Castro
Mohammad Alomari, Mamoon Ur Rashid, Pravallika Chadalavada, Jonathan Ragheb, Hammad Zafar, Adalberto Jose Gonzalez, Fernando J Castro, Department of Gastroenterology and Hepatology, Cleveland Clinic Florida, Weston, FL 33331, United States
Zoilo Karim Suarez, Department of Internal Medicine, Florida Atlantic University Charles E Schmidt College of Medicine, Boca Raton, FL 33431, United States
Shrouq Khazaaleh, Department of Internal Medicine, Cleveland Clinic Fairview Hospital, Cleveland, OH 44126, United States
Author contributions: Alomari M, Rashid MU, Chadalavada P, Ragheb J, Zafar H, Suarez ZK, Khazaaleh S, Gonzalez A, and Castro F contributed to the article design, writing, proofreading, and revision.
Conflict-of-interest statement: There was no external funding used in preparing our manuscript. Our authors have no financial relationship to the work, receive no government or company grants or research support, and are neither employees nor consultants for a pharmaceutical company. We are not stockholders of a pharmaceutical company or members of a speaker’s bureau.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Mohammad Alomari, MD, Academic Fellow, Department of Gastroenterology and Hepatology, Cleveland Clinic Florida, 2950 Cleveland Clinic Blvd, Weston, FL 33331, United States. dr_mohd1987@hotmail.com
Received: December 27, 2022
Peer-review started: December 27, 2022
First decision: January 19, 2023
Revised: February 4, 2023
Accepted: March 22, 2023
Article in press: March 22, 2023
Published online: April 27, 2023
Abstract

As a result of the obesity epidemic, Nonalcoholic fatty liver disease (NAFLD) and its complications have increased among millions of people. Consequently, a group of experts recommended changing the term NAFLD to an inclusive terminology more reflective of the underlying pathogenesis; metabolic-associated fatty liver disease (MAFLD). This new term of MAFLD has its own disease epidemiology and clinical outcomes prompting efforts in studying its differences from NAFLD. This article discusses the rationale behind the nomenclature change, the main differences, and its clinical implications.

Keywords: Metabolic associated fatty liver disease, Non alcoholic fatty liver disease, Fatty liver disease, Obesity, Diabetes mellitus

Core Tip: A new nomenclature to represent the underlying pathophysiology of fatty liver disease has been created and labeled metabolic-associated fatty liver disease. This article discusses the rationale behind the nomenclature change, the main differences to nonalcoholic fatty liver disease, and its clinical implications.